These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30930066)

  • 1. Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity.
    Shrestha R; Garrett SC; Almo SC; Fiser A
    Structure; 2019 May; 27(5):829-836.e3. PubMed ID: 30930066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
    Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals.
    Philips EA; Garcia-España A; Tocheva AS; Ahearn IM; Adam KR; Pan R; Mor A; Kong XP
    J Biol Chem; 2020 Apr; 295(14):4372-4380. PubMed ID: 31882544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and interactions of the human programmed cell death 1 receptor.
    Cheng X; Veverka V; Radhakrishnan A; Waters LC; Muskett FW; Morgan SH; Huo J; Yu C; Evans EJ; Leslie AJ; Griffiths M; Stubberfield C; Griffin R; Henry AJ; Jansson A; Ladbury JE; Ikemizu S; Carr MD; Davis SJ
    J Biol Chem; 2013 Apr; 288(17):11771-85. PubMed ID: 23417675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding.
    Shin J; Phelan PJ; Gjoerup O; Bachovchin W; Bullock PA
    Protein Expr Purif; 2021 Jan; 177():105766. PubMed ID: 32987122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression,
    Morales-Betanzos CA; Lee H; Gonzalez Ericsson PI; Balko JM; Johnson DB; Zimmerman LJ; Liebler DC
    Mol Cell Proteomics; 2017 Oct; 16(10):1705-1717. PubMed ID: 28546465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy.
    Lázár-Molnár E; Scandiuzzi L; Basu I; Quinn T; Sylvestre E; Palmieri E; Ramagopal UA; Nathenson SG; Guha C; Almo SC
    EBioMedicine; 2017 Mar; 17():30-44. PubMed ID: 28233730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Non-IgG PD-1/PD-L1 Inhibitor by
    Ning B; Ren X; Hagiwara K; Takeoka S; Ito Y; Miyatake H
    ACS Chem Biol; 2021 Feb; 16(2):316-323. PubMed ID: 33448787
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Li K; Cheng X; Tilevik A; Davis SJ; Zhu C
    J Biol Chem; 2017 Apr; 292(16):6799-6809. PubMed ID: 28270509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanical force regulates ligand binding and function of PD-1.
    Li K; Cardenas-Lizana P; Lyu J; Kellner AV; Li M; Cong P; Watson VE; Yuan Z; Ahn E; Doudy L; Li Z; Salaita K; Ahmed R; Zhu C
    Nat Commun; 2024 Sep; 15(1):8339. PubMed ID: 39333505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A computational study of co-inhibitory immune complex assembly at the interface between T cells and antigen presenting cells.
    Su Z; Dhusia K; Wu Y
    PLoS Comput Biol; 2021 Mar; 17(3):e1008825. PubMed ID: 33684103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering Cholesterol's Role in PD-L2 Stability: A Distinct Regulatory Mechanism From PD-L1.
    Zhang Y; Xiao T; Wen M; Shen L; Du L; Wei S; Wu B; Yu Y; Wang S; OuYang B
    J Mol Biol; 2024 Apr; 436(8):168500. PubMed ID: 38401626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD).
    Du J; Qin Y; Wu Y; Zhao W; Zhai W; Qi Y; Wang C; Gao Y
    Cell Commun Signal; 2018 Jun; 16(1):25. PubMed ID: 29879980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases.
    Ibañez-Vega J; Vilchez C; Jimenez K; Guevara C; Burgos PI; Naves R
    J Autoimmun; 2021 Sep; 123():102702. PubMed ID: 34311143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.
    Almahmoud S; Zhong HA
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach.
    Paciotti R; Agamennone M; Coletti C; Storchi L
    J Comput Aided Mol Des; 2020 Aug; 34(8):897-914. PubMed ID: 32185582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
    Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
    Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.